Saturday 29 November 2003
CDKN1A (p21) and CDKN1B (p27 or KIP1) block the cell cycle by binding to cyclin-CDK complexes. p21 is induced by the tumor suppressor p53 (TP53).
CDKN1B (p27 or KIP1) responds to growth suppressors such as transforming growth factor-β (TGFBs).
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP (20371683).
- p21 protein expression emerged as an important independent predictor of a favorable clinical outcome when rituximab was added to CHOP therapy.
- rituximab-related effects on lymphoma survival pathways may be functionally linked to p21 activity.
Cip/Kip family: CDKN1A (p21) and CDKN1B (p27 or KIP1)
Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2006 Jan;6(1):11-23. PMID: 16372018
Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005 May 15;65(10):3980-5. PMID: 15899785